Combatting HIV Or Other STIs Early (CHOOSE) (CHOOSE)

May 19, 2026 updated by: Westat

Combatting HIV Or Other STIs Early (CHOOSE): An Integrated Strategy of Pre-Exposure Prophylaxis (PrEP) Mobile Health (mHealth) Support and Doxycycline Post-Exposure Prophylaxis (DoxyPEP)

The overarching goal of this project is to optimize the PrEP Choice integrated mHealth package and assess the efficacy and cost of PrEP Choice on PrEP initiation and adherence among young people. It is hypothesized that PrEP Choice will improve HIV PrEP uptake and adherence among young people and will be cost-effective to deliver to young people in the United States (U.S.). This study will also assess the uptake, adherence, and acceptability of DoxyPEP among young people.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

This is an individual-level randomized trial with a wait-list control and provides PrEP and DoxyPEP for study participants at the Adolescent Medicine Trials Network for HIV Interventions (ATN) Site Consortiums (SCs). This study will be conducted to determine the efficacy and cost of the PrEP Choice package on initiation and long-term adherence (persistence) of PrEP use over 18 months among young people (n=200). All participants will receive brief, basic counseling about the different PrEP methods and a PrEP handout from the participating SC. They will also receive counseling and a handout about DoxyPEP. Participants in the intervention arm will receive the PrEP Choice package starting at enrollment. Participants in the control arm will receive the PrEP Choice package starting at 9 months after enrollment. Both intervention and control groups will be followed for a total of 18 months.

All PrEP drugs will be dispensed by the participating SCs. Participants can select from the following PrEP agents and regimens:

(1) daily oral tenofovir/emtricitabine (tenofovir disoproxil fumarate [TDF]/emtricitabine [FTC]; (2) daily oral tenofovir alafenamide (TAF)/FTC; (3) 2-1-1 event-driven oral TDF/FTC; (4) bimonthly long-acting injectable cabotegravir (CAB-LA); or (5) twice yearly long-acting injectable lenacapavir (LEN). Participants can opt to start PrEP or change regimens at any time in the 18 months of follow-up. At 9 months, participants originally randomized to the control condition will begin to receive the PrEP Choice package in a wait-list control design. This addresses ethical concerns about withholding a potentially effective intervention from the control arm for an extended period. This design also allows for comparison both between arms (intervention versus control), as well as within arms (before versus after the PrEP Choice package in control arm) and allows measurement of extended outcomes and switching patterns for those initially randomized to the PrEP Choice package over 18 months. In addition, DoxyPEP will be offered to both study arms throughout the study.

Study Type

Interventional

Enrollment (Estimated)

200

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • United States
    • California
      • San Francisco, California, United States, 94102
        • San Francisco Department of Public Health
        • Principal Investigator:
          • Albert Liu
        • Contact:
    • District of Columbia
      • Washington D.C., District of Columbia, United States, 20010
        • Children's National Medical Center
        • Principal Investigator:
          • Natella Rakhmanina
        • Contact:
    • Florida
      • Tampa, Florida, United States, 33612
        • University of South Florida
        • Contact:
        • Principal Investigator:
          • Patricia Emmanuel
    • Illinois
      • Chicago, Illinois, United States, 60612
        • University Illinois Chicago
        • Contact:
        • Principal Investigator:
          • Kelly Bojan
    • Louisiana
      • New Orleans, Louisiana, United States, 70112
        • Tulane University
        • Principal Investigator:
          • Tina Simpson
        • Contact:
    • Tennessee
      • Memphis, Tennessee, United States, 38015
        • St. Jude Children's Research Hospital
        • Contact:
        • Principal Investigator:
          • Aditya Gaur

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria

  • Age 13-24 years, inclusive;
  • Self-reports being at increased likelihood for HIV acquisition, defined as having anal sex with a male in their lifetime;
  • Owns an iOS or Android Smartphone and able to access all elements of the PrEP Choice package;
  • Not currently on PrEP and interested in learning more about PrEP;
  • Is not living with HIV;
  • Weighs at least 35 kg;
  • Willing to receive PrEP care from a provider at a participating ATN SC;
  • Able to understand, read, and speak English;
  • Able to participate at the study site; and
  • Willing and able to provide written informed consent.
  • If of legal age or otherwise able to provide independent informed consent as determined by local law and consistent with IRB policies: Willing and able to provide written informed consent for study participation.
  • If not of legal age or otherwise not able to provide independent informed consent as determined by local law and consistent with IRB policies: Parent or legal guardian is willing and able to provide written informed consent for study participation and potential participant is willing and able to provide written assent for study participation.

Exclusion Criteria:

  • Female;
  • In a mutually monogamous sexual relationship with a partner not living with HIV for the past 12 months;
  • Currently participating in an interventional trial of PrEP agents, or prior enrollment in HPTN 083, HPTN 083-01, or any other study of long-acting PrEP (including PURPOSE- 2 lenacapavir study);
  • Plan to move within 18 months to an area inaccessible to a participating ATN SC;
  • An employee of the participating SC; or
  • Any concurrent participation in other clinical trials or behavioral intervention studies without prior approval from the protocol team.
  • Any other medical, behavioral, or other conditions that in the opinion of the SC Project Lead could interfere with adherence to study procedures or the individual's ability to remain in the study for an 18-month period or compromise interpretation of study results.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Standard of Care and PrEP Choice at Enrollment
Participants randomized to the intervention arm will be onboarded PrEP Choice at their Enrollment Visit.
Other: Standard of care and PrEP Choice at Enrollment

Standard of care includes a handout describing the different PrEP regimens as well as a handout describing DoxyPEP.

PrEP Choice is a package of three mHealth tools:

  1. MyPrEP, a decision support website to help PrEP users choose their optimal PrEP method;
  2. PrEPsmart, a mobile app to support PrEP adherence for persons using on-demand PrEP (2-1-1 oral PrEP) by providing dosing reminders and feedback on levels of protection; and PrEPmate, a bidirectional short message service (SMS) texting platform with automated daily reminders for oral PrEP users and a triage function to help those experiencing difficulties.
Active Comparator: Standard of care for the first 9 months followed by initiation of PrEP Choice at Month 9
Participants randomized to the delayed arm will be onboarded to PrEP Choice at their Month 9 study visit.
Other: Standard of care followed by PrEP Choice at Month 9

Standard of care includes a handout describing the different PrEP regimens as well as a handout describing DoxyPEP.

PrEP Choice is a package of three mHealth tools:

  1. MyPrEP, a decision support website to help PrEP users choose their optimal PrEP method;
  2. PrEPsmart, a mobile app to support PrEP adherence for persons using on-demand PrEP (2-1-1 oral PrEP) by providing dosing reminders and feedback on levels of protection; and PrEPmate, a bidirectional short message service (SMS) texting platform with automated daily reminders for oral PrEP users and a triage function to help those experiencing difficulties.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PrEP Uptake; proportion of participants receiving PrEP from the study site within 9 months of study follow-up
Time Frame: first 9 months of follow up

1. PrEP uptake; the proportion of participants receiving PrEP from the study site within 9 months of study follow-up.

PrEP uptake is binary, indicating whether the study participant has received PrEP from the study site. This endpoint compares the proportion of participants who receive PrEP from the study site within the first 9 months of study follow-up between the treatment arms.
first 9 months of follow up
PrEP Adherence; rate at which participants who received PrEP on study adhere to selected PrEP regimen as measured by dried blood spot for oral regimen and by the on-time CAB-LA and LEN injections for injectable PrEP
Time Frame: first 9 months of follow-up

1. PrEP adherence, the rate at which participants who received PrEP on study adhere to the selected PrEP regimen as measured by dried blood spot for participants selecting an oral regimen and by the on-time CAB-LA and LEN injections for participants opting for injectable PrEP through the first 9 months of study follow-up.

PrEP adherence, as measured by dried blood stop for participants selecting an oral regimen and by the on-time CAB-LA and LEN injections for participants option for injectable PrEP, will be assessed every 3 months, and the rate at 9 months of study follow-up will be compared between arms.
first 9 months of follow-up
DoxyPEP Uptake; the rate at which participants receive DoxyPEP from the study site
Time Frame: 18 months of follow up

1. DoxyPEP uptake, the rate at which participants receive DoxyPEP from the study site within 18 months of study follow-up.

DoxyPEP uptake is binary, indicating whether the study participant has received DoxyPEP from the study site. This endpoint compares the rates of participants who receive DoxyPEP from the study site, assessed every 3 months through the 18 months of study follow-up, between treatment conditions. Participants will be analyzed according to the treatment received, so participants on the delayed treatment arm will be considered on PrEP Choice once they cross over at 9 months.
18 months of follow up
DoxyPEP Adherence; the rate at which participants are adherent to DoxyPEP coverage of condomless sexual exposures as measured by self-report
Time Frame: 18 months of follow up

1. DoxyPEP adherence, the rate at which participants are adherent to DoxyPEP coverage of condomless sexual exposures as measured by self-report.

DoxyPEP adherence is binary, indicated whether the study participant used DoxyPEP to cover their last condomless sexual exposure. This endpoint will be assessed every 3 months through 18 months of study follow-up and compared between treatment conditions. Participants will be analyzed according to the treatment received, so participants on the delayed treatment arm will be considered on PrEP Choice once they cross over at 9 months.
18 months of follow up
DoxyPEP Acceptability; assessed by Likert scale every 3 months of study follow-up
Time Frame: 18 months of follow up

DoxyPEP acceptability, assessed by Likert scale every 3 months of study follow-up through 18 months of follow-up.

DoxyPEP acceptability Likert scale results will be compared between the treatment conditions, assessed every 3 months through 18 months of study follow-up. Participants will be analyzed according to the treatment received, so participants on the delayed treatment arm will be considered on PrEP Choice once they cross over at 9 months.

The Likert Scale is as follows:

  1. Very acceptable
  2. Somewhat acceptable
  3. Neither acceptable nor unacceptable
  4. Somewhat unacceptable
  5. Very unacceptable
18 months of follow up

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PrEP modality choice and switching
Time Frame: 18 months of follow up
PrEP modality choice and switching, the proportion of participants who choose each PrEP regimen initially, the proportion of participants within each regimen who switch to another regimen, and the proportion of participants who choose each PrEP regimen with their second choice, among those who switch initial PrEP regimens through 18 months of study follow-up.
18 months of follow up
PrEP Adherence; rate at which participants who received PrEP on study adhere to selected PrEP regimen as measured by dried blood spot for oral regimen and by the on-time CAB-LA and LEN injections for injectable PrEP
Time Frame: 18 months of follow up

7. PrEP adherence, the rate at which participants who received PrEP on study adhere to the selected PrEP regimen as measured by dried blood spot for participants selecting an oral PrEP regimen and by the on-time CAB-LA and LEN injections for participants opting for injectable PrEP through the 18 months of study follow-up.

PrEP adherence, as measured by dried blood spot for participants selecting an oral regimen and by the on-time CAB-LA and LEN injections for participants opting for injectable PrEP, will be assessed every 3 months, and the rate at 18 months of study follow-up will be compared between treatment conditions. Participants will be analyzed according to the treatment received, so participants on the delayed treatment arm will be considered on PrEP Choice once they cross over at 9 months.
18 months of follow up
STI Incidence; individual and combined rates of gonorrhea, chlamydia, and/or early syphilis infection compared between DoxyPEP users and non-users, assessed every 3 months
Time Frame: 18 months of follow-up
STI incidence, individual and combined rates of gonorrhea, chlamydia, and/or early syphilis infection compared between DoxyPEP users and non-users, assessed every 3 months through 18 months of study follow-up. STIs will be assessed by STI testing at the site every 3 months through 18 months of study follow-up. Combined STI incidence is defined as having at least 1 STI at a study visit. Rates of STI will be compared between users of DoxyPEP and non-users through 18 months of study follow-up. Participants will be classified as a user or non-user at each study assessment based on their self-reported use since the last assessment.
18 months of follow-up
DoxyPEP Uptake; the rate at which participants receive DoxyPEP from the study site
Time Frame: First 9 months of follow-up

9. DoxyPEP uptake, the rate at which participants receive DoxyPEP from the study site within 9 months of study follow-up.

DoxyPEP uptake is binary, indicated whether the study participant has received DoxyPEP from the study site. This endpoint compares the rates of participants who receive DoxyPEP from the study site, assessed every 3 months, through the first 9 months of study follow-up, between treatment arms.
First 9 months of follow-up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Westat

Collaborators

National Institute on Drug Abuse (NIDA)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute of Mental Health (NIMH)
National Institutes of Health (NIH)
Florida State University
The Emmes Company, LLC

Investigators

  • Principal Investigator: Lisa Hightow-Weidman, MD, MPH, Florida State University
  • Study Chair: Susan Buchbinder, San Francisco Department of Public Health
  • Study Chair: Albert Liu, San Francisco Department of Public Health
  • Principal Investigator: Sybil Hosek, PhD, University of Illinois at Chicago

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 1, 2026

Primary Completion (Estimated)

September 1, 2029

Study Completion (Estimated)

September 1, 2029

Study Registration Dates

First Submitted

February 24, 2026

First Submitted That Met QC Criteria

March 27, 2026

First Posted (Actual)

April 3, 2026

Study Record Updates

Last Update Posted (Actual)

May 22, 2026

Last Update Submitted That Met QC Criteria

May 19, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ATN166 Phase 2

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on HIV

Clinical Trials on Standard of care and PrEP Choice at Enrollment

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe